Comparison of the effect of Dexamethasone with Ondansetron on nausea and vomiting in adults undergoing upper GI endoscopy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230926059530N1

Enrollment

102

Registered

2023-10-24

Start date

2023-10-06

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diseases of the digestive system. Diseases of the digestive system

Interventions

Intervention 1: Intervention group: Receive 8mg of intravenous dexamethasone before upper gastrointestinal endoscopy. Intervention 2: Intervention group: Receive 8mg of intravenous Ondansetron before

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: All patients between 18 and 70 years of age, group I and II criteria of ASA candidate for elective UGIE diagnosis based on the opinion of a gastroenterologist

Exclusion criteria

Exclusion criteria: No history of allergy to the drugs used in the study No history of chemotherapy Not receiving any anti-nausea medication 24 hours before endoscopy No history of malignancy

Design outcomes

Primary

Measure	Time frame
Nausea and vomiting. Timepoint: After upper gastrointestinal endoscopy. Method of measurement: Patient self-expression.;Cough. Timepoint: After upper gastrointestinal endoscopy. Method of measurement: Patient self-expression.;Sore throat. Timepoint: After upper gastrointestinal endoscopy. Method of measurement: Patient self-expression.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Zamanian Najafabadi

Kashan University of Medical Sciences

Alizamanian9674@gmail.com+98 31 4251 0991

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026